Millennium Management
BTAI icon

Millennium Management’s BioXcel Therapeutics BTAI Stock Holding History

Millennium Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,475
Closed -$264K – 6145
2023
Q2 		$264K Sell
2,475
-3,775
-60% -$1.26M ﹤0.01% 4974
2023
Q1 		$1.87M Buy
+6,250
New +$2.67M ﹤0.01% 3513

Other funds holding BTAI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management's BTAI Position: Q1 2026 in Review

Millennium Management increased its BioXcel Therapeutics (BTAI) stake by 5.5% in Q1 2026, buying an estimated $167K and bringing the position to 1,936,760 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3614.

Millennium Management first reported a position in BTAI in Q1 2018 and has held it in 19 quarters since. The position peaked at $2.94M in Q4 2025. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • Millennium Management held 1,936,760 shares of BioXcel Therapeutics worth $2.6M as of Q1 2026.
  • Millennium Management bought 101,568 BioXcel Therapeutics shares in Q1 2026, an estimated $167K.
  • BioXcel Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3614 holding.
  • Millennium Management first reported a position in BioXcel Therapeutics in Q1 2018 and has held it in 19 quarters since.
  • Millennium Management's BioXcel Therapeutics position peaked at $2.94M in Q4 2025.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.